S. David Grayzel's Insider Trades & SAST Disclosures
S. David Grayzel's most recent trade in Q32 Bio Inc. was a trade of 18,595 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern S. David Grayzel.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Q32 Bio Inc. | Grayzel S. David | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 18,595 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Grayzel S. David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 18,595 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | S. David Grayzel | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 0 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | Grayzel David S. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | S. Grayzel David | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 15 Jan 2025 | 2,569 | 0 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Sale of securities on an exchange or to another person at price $ 28.15 per share. | 09 Apr 2024 | 11,882 | 14,502 | - | 28.1 | 334,478 | Common Stock |
| Q32 Bio Inc. | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 2,569 | 2,569 | - | - | Stock Option (Right to Buy) | |
| Q32 Bio Inc. | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2024 | 12,767 | 12,767 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | S. David Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,186 | 3,186 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 2,654 | 2,654 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 7,317 | 7,317 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | 01 Jul 2021 | 7,976,754 | 0 | - | - | Series A Preferred Stock | ||
| Jade Biosciences Inc | David S. Grayzel | Director | 01 Jul 2021 | 2,568,165 | 2,568,165 | - | - | Common Stock | ||
| Jade Biosciences Inc | David S. Grayzel | Director | Purchase of securities on an exchange or from another person at price $ 14.00 per share. | 01 Jul 2021 | 535,714 | 3,103,879 | - | 14 | 7,499,996 | Common Stock |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2021 | 2,153 | 2,153 | - | - | Stock Option (Right to Buy) | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 6,102,052 | 7,976,754 | - | - | Series A Preferred Stock | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 878,981 | 1,874,702 | - | - | Series A Preferred Stock | |
| Jade Biosciences Inc | David S. Grayzel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges